SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is facing intense bearish pressure as the stock touches multi-year lows, driven by weak consumer demand, ongoing competition, and widespread skepticism regarding the success of current turnaround efforts. While many in the community are debating whether this represents a generational buying opportunity at a deep discount or a value trap signaling further downside, others are calling for aggressive management changes and are closely watching upcoming dividend dates.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlist Inc. is experiencing significant investor interest driven by a combination of a newly established five-year alliance with Samsung and ongoing, high-stakes legal battles with major memory manufacturers. The community is actively debating the company's valuation potential as it navigates these litigation milestones and anticipates further licensing deals, fueling a strong bullish sentiment among long-term holders.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is facing significant selling pressure as investors weigh the potential long-term financial impact of a high-profile multi-state lawsuit regarding platform impact on minors. While the company's core advertising business remains profitable, community discourse is split between those viewing the pullback as a value-buying opportunity and critics concerned that heavy AI capital expenditures may take longer than expected to yield sustainable returns.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors digest recent institutional accumulation and anticipate upcoming clinical data updates, including a pivotal presentation at the ASTRO conference in late September. Community discussions remain highly focused on the potential for a massive acquisition by a major pharmaceutical firm, alongside ongoing developments for their lead candidate, aglatimagene besadenovec, as it heads toward a BLA filing later this year.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is seeing massive volatility and heavy trading volume as traders react to strong earnings and aggressive growth guidance, while the community intensely debates whether the price action is a legitimate breakout or a short-squeeze bubble. Longs are focused on the company's monopoly in wafer-level burn-in for AI chips, while bears are aggressively shorting the stock, citing extreme valuations and recurring insider selling as signals of an impending correction.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegian Cruise Line Holdings is trending amid ongoing community debate over recent earnings guidance, with many retail investors expressing frustration over the stock's volatility and performance compared to sector peers. The sentiment is heavily polarized, featuring traders actively debating the impact of Elliott Management's stake, concerns regarding long-term debt and fuel costs, and widespread claims of algorithmic manipulation by institutional players.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology is currently trending as investors weigh strong revenue growth projections against uncertainty surrounding the timing of upcoming financial results and the potential for share dilution. The community is actively debating the stock's long-term potential in AI infrastructure while closely monitoring technical price levels and elevated short interest as a potential catalyst for volatility.

Duos Technologies Group, Inc. designs, develops, deploys, and operates intelligent technology solutions supporting rail, logistics, intermodal and government customers that streamlines operations, improves safety and reduces costs. It offers imaging, safety and security, software, and services. The firm also provides cutting edge solutions that automate the mechanical and security inspection of fast moving trains, trucks and automobiles through a broad range of proprietary hardware, software, information technology and artificial intelligence. The company was founded on May 31, 1994 and is headquartered in Jacksonville, FL.

Duos Technologies Group Inc

Duos Technologies is trending as investors digest a massive five-year, 55 MW hosting agreement with Axe Compute valued at over $500 million, which has fueled community optimism about the company's aggressive AI infrastructure build-out. While some participants are closely debating the company's ability to deliver on these ambitious timelines and the potential for share dilution, many are highlighting the firm's strategic positioning in the high-demand edge computing sector as a significant long-term growth catalyst.

Icahn Enterprises LP is a holding company. It operates through the following segments: Investment, Automotive, Energy, Food Packaging, Real Estate, Home Fashion, Pharma, and Holding Company. The Investment segment consists of various private investment funds. The Automotive segment holds ownership in Icahn Automotive Group, LLC. The Energy segment refers to petroleum refining and marketing businesses. The Food Packaging segment involves the production and sale of cellulosic, fibrous, and plastic casings for the processed meat and poultry industry. The Real Estate segment offers rental real estate, property development, and resort activities. The Home Fashion segment deals with manufacturing, sourcing, marketing, distributing, and selling home fashion consumer products. The Pharma segments operate through Vivus, Inc., a specialized pharmaceutical company. The Holding Company segment manages acquisition and investment in operating businesses. The company was founded on February 17, 1987 and is headquartered in Sunny Isles Beach, FL.

Icahn Enterprises L P - Unit

Icahn Enterprises, L.P.

Icahn Enterprises is trending as investors monitor the company's Q2 2026 earnings, focusing on the potential for asset recovery and the sustainability of its quarterly distribution despite a lower share price. The community is actively debating the disparity between GAAP valuations and underlying asset value, while weighing the impact of strategic portfolio moves, such as the sale of Pep Boys and potential energy sector tailwinds, against the risks of heavy short interest and ongoing share dilution.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is gaining significant momentum as investors digest recent positive earnings and look ahead to potential revenue guidance upgrades, with the community closely tracking institutional accumulation and a massive short interest setup that could trigger a squeeze. Sentiment is increasingly bullish as traders focus on the upcoming lung cancer clinical data readouts and the potential for long-term multi-indication growth in the oncology space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tiziana Life Sciences Says Imaging Results Show Neuroinflammation Reduction in Rare Neurodegenerative Condition

Tiziana Life Sciences reports reduced brain inflammation in its third Phase 2 trial patient treated with intranasal foralumab for MSA.read more...

Tiziana Life Sciences Stock Rises Over 9% After Multiple Sclerosis Trial Enrollment Update

Equity

The biotechnology company has completed enrollment in its placebo-controlled study of intranasal foralumab, with late-stage data expected in 2026.

Wall Street Zen Downgrades Tiziana Life Sciences (NASDAQ:TLSA) to Sell

Wall Street Zen lowered Tiziana Life Sciences from a "hold" rating to a "sell" rating in a research note on Saturday...

Tiziana Life Sciences (NASDAQ:TLSA) Trading 6.8% Higher - Here's What Happened

Tiziana Life Sciences (NASDAQ:TLSA) Trading 6.8% Higher - Here's What Happened...

Tiziana Life Sciences Stock Jumps As Positive Preclinical Fuels Momentum

Tiziana Life Sciences shares jump on intranasal foralumab data, while technical indicators point to mixed momentum.read more...

Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Down 4.4% - Should You Sell?

Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 4.4% - Should You Sell...

Tiziana Life Sciences (NASDAQ:TLSA) Trading Up 0.7% - Here's What Happened

Tiziana Life Sciences (NASDAQ:TLSA) Shares Up 0.7% - Should You Buy...

Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Up 3.1% - Should You Buy?

Tiziana Life Sciences (NASDAQ:TLSA) Trading 3.1% Higher - Still a Buy...

Tiziana Life Sciences (NASDAQ:TLSA) Trading Up 7.4% - Still a Buy?

Tiziana Life Sciences (NASDAQ:TLSA) Shares Up 7.4% - What's Next...

Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 4.4% - Here's Why

Tiziana Life Sciences (NASDAQ:TLSA) Shares Down 4.4% - Should You Sell...

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in developing therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Alzheimer’s. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.

Tiziana Life Sciences Ltd

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1.14
Prev Close	$1.14
Open	$1.11
Dividend Yield	0.00%
50-Day Moving Average	$1.11
Beta	0.68
Avg. Volume	259,841.36
PE Ratio	-7.28

52-Week High	$2.35
52-Week Low	$0.8663
Market Capitalization	$145.63M
EPS (Annual)	-$0.1558
Price to Book	2,639.53
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info